Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
News|Slideshows|May 31, 2022
Chronic Migraine: Why we Get it Wrong, Why it Matters
Author(s)Peter McAllister, MD
Episodic or chronic? Distinguishing between the 2 types of migraine is essential to ensure optimal treatment. Meet Abigail and Martin. Who has which headache?
Advertisement
Advertisement
Related to this article
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
Plasma p-tau217 levels helped estimate 5- and 10-year cognitive impairment risk in older adults without memory or thinking symptoms.
FDA cleared C2N’s PrecivityAD2 blood test to aid Alzheimer disease evaluation in symptomatic adults aged 40 years and older.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Advertisement
Advertisement
Trending on Patient Care Online
1
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
2
FDA Grants Priority Review to Elinzanetant for VMS in HR+ Breast Cancer Patients on Endocrine Therapy
3
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
4
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
5